Molecular Lipids Identify Cardiovascular Risk and Are Efficiently Lowered by Simvastatin and PCSK9 Deficiency

• Published in: The journal of clinical endocrinology and metabolism Vol. 99; no. 1; pp. E45 - E52
• Main Authors: Tarasov, Kirill, Ekroos, Kim, Suoniemi, Matti, Kauhanen, Dimple, Sylvänne, Tuulia, Hurme, Reini, Gouni-Berthold, Ioanna, Berthold, Heiner K., Kleber, Marcus E., Laaksonen, Reijo, März, Winfried
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01.01.2014; Copyright by The Endocrine Society; Endocrine Society
• Subjects: Aged; Azetidines - therapeutic use; Cardiovascular disease; Cardiovascular diseases; Case-Control Studies; Ceramide; Cholesterol; Coronary artery disease; Coronary Artery Disease - blood; Coronary Artery Disease - drug therapy; Coronary Artery Disease - epidemiology; Drug development; Ezetimibe; Female; Follow-Up Studies; Genetic Association Studies; Genetic Predisposition to Disease; Heart diseases; Hot Topics in Translational Endocrinology; Humans; Hypolipidemic Agents - therapeutic use; Lipids; Lipids - blood; Macromolecular Substances - blood; Male; Middle Aged; Morbidity; Proprotein Convertase 9; Proprotein Convertases - deficiency; Proprotein Convertases - genetics; Randomized Controlled Trials as Topic; Risk Factors; Serine Endopeptidases - deficiency; Serine Endopeptidases - genetics; Simvastatin; Simvastatin - therapeutic use

Context:Coronary artery disease (CAD) is among the leading causes of mortality and morbidity worldwide. Traditional risk markers explain only a proportion of total cardiovascular risk. Thus, development and improvement of early diagnostic strategies and targeted initiation of preventive measures wou...